StreetInsider.com News Articles

Alebund's AP301 NDA Accepted for Review by China's NMPA

Fri, 07 Aug 2026 06:34:00 -0400

SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving maintenance dialysis, is formally accepted for review by China's National Medical Products Administration (NMPA) today. The NDA is supported primarily by the results of RESPOND-1, the pivotal Phase III clinical trial of AP301 completed in China, together with

Alebund's AP301 NDA Accepted for Review by China's NMPA

Fri, 07 Aug 2026 06:34:00 -0400

Alebund's AP301 NDA Accepted for Review by China's NMPA

Fri, 07 Aug 2026 06:34:00 -0400

Alebund's AP301 NDA Accepted for Review by China's NMPA

Fri, 07 Aug 2026 06:34:00 -0400

Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia

Tue, 21 Jul 2026 07:00:00 -0400

SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (NCT06712654). The trial is being conducted at multiple clinical sites in the United States and China and is co-sponsored by Alebund and R1 Therapeutics, Inc. ("R1").